Amarin Corp. (AMRN) announced a $100 million non-equity financing after the bell Thursday with an investment fund managed by Pharmakon Advisors. Amarin is continuing its preparations to commercialize Vascepa capsules with the hiring of a sales force in the United States.
Amarin gapped open sharply lower Friday, but traded in a narrow range throughout the session. The stock closed down by 2.26 at $9.69, with volume at over a 4-month high. Amarin dropped below a 2-month range and set over a 6-month low.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org